EP2508188

ASTRAZENECA AB
Application Number
EP12153939A
Filing Date
Mar 21, 2008
Status
Granted And Under Opposition
Apr 7, 2023
Grant Date
May 10, 2023
External Links
Slate, Register

Biblio Summary

The patent EP2508188B1 was granted on May 10, 2023 by Astrazeneca Ab The patent is currently Granted And Under Opposition.

The table below shows 5 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH S.L.U.Feb 9, 2024ADMISSIBLE
GEDEON RICHTER PLC.Feb 9, 2024ADMISSIBLE
GENERICS UKFeb 9, 2024ADMISSIBLE
KRAUS & LEDERER PARTGMBBFeb 9, 2024ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBFeb 6, 2024ADMISSIBLE

The table below shows the patents of Astrazeneca Ab that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3045466(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of DiabetesOct 16, 20241
EP4114465Anti-Ifnar1 Dosing Regime For Subcutaneous InjectionAug 30, 20231
EP3769781Stable Anti-Ifnar1 FormulationApr 19, 20231